Caerus Investment Advisors LLC Buys New Shares in Medpace Holdings, Inc. $MEDP

Caerus Investment Advisors LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,577 shares of the company’s stock, valued at approximately $811,000.

A number of other large investors have also bought and sold shares of the stock. Quent Capital LLC bought a new position in shares of Medpace during the 3rd quarter worth about $25,000. Optiver Holding B.V. bought a new stake in Medpace in the 3rd quarter valued at about $27,000. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Quarry LP acquired a new position in Medpace during the 3rd quarter worth approximately $35,000. Finally, Employees Retirement System of Texas acquired a new position in Medpace during the 2nd quarter worth approximately $36,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Price Performance

MEDP opened at $455.15 on Wednesday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The firm has a market capitalization of $12.92 billion, a PE ratio of 29.75, a P/E/G ratio of 2.17 and a beta of 1.44. The company’s 50-day moving average is $517.88 and its 200 day moving average is $539.13.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

MEDP has been the subject of a number of research reports. Truist Financial reduced their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Mizuho set a $582.00 price target on shares of Medpace in a research report on Wednesday, February 11th. Finally, Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a report on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.